Monday, November 10, 1997
One plus one plus one can occasionally equal four. That, at least, is
the hope of LeukoSite Inc. and its partners Warner-Lambert and Kyowa Hakko Kogyo Co. Ltd.
The partners were to announce today that they are taking two separate alliances, modifying
the terms, and combining them into a single chemokine drug discovery partnership for the
treatment of inflammatory and autoimmune diseases.
Warner-Lambert and LKST began collaborating in 1994. Under the original
deal, the pharma company had exclusive rights to small molecule antagonists of the MCP-1
receptor. The chemokine MCP-1 recruits monocytes and T cells from the bloodstream to
tissues and has been implicated in the chronic inflammatory processes associated with
rheumatoid arthritis and atherosclerosis.